They also talked about running at least one additional study (didn't catch if they said others). It would be in children under age 5 if they get FDA approval to do so. It wouldn't be a registration study more of a label expansion strategy. With so many patients I thought while it may cost more if they ran a second study measuring growth rate then if something happens in the shorter study (I think 24 weeks is what they said) then they still have the other study as a fallback option.
News 
Market Data 
Discover 
